We are live on ! Find out more
BBIO icon

BridgeBio Pharma
BBIO

210 hedge funds and large institutions have $6.56B invested in BridgeBio Pharma in 2021 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 83 increasing their positions, 61 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 18

36% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 61

5% more funds holding

Funds holding: 200 → 210 (+10)

0% more funds holding in top 10

Funds holding in top 10: 15 → 15 (0)

2.04% less ownership

Funds ownership: 95.52% → 93.48% (-2%)

22% less call options, than puts

Call options by funds: $19.6M | Put options by funds: $25M

22% less capital invested

Capital invested by funds: $8.46B → $6.56B (-$1.9B)

Holders
210
Holders Change
+10
Holders Change %
+5%
% of All Funds
3.68%
Holding in Top 10
15
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.26%
New
30
Increased
83
Reduced
61
Closed
18
Calls
$19.6M
Puts
$25M
Net Calls
-$5.4M
Net Calls Change
+$4.12M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$34.4M
2
Fisher Asset Management
Fisher Asset Management
Washington
+$30.5M
3
State Street
State Street
Massachusetts
+$23.1M
4
Charles Schwab
Charles Schwab
California
+$17.2M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$16.2M

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$102M
2
IAM
Iridian Asset Management
Connecticut
-$59.9M
3
EAM
Eventide Asset Management
Massachusetts
-$43.4M
4
APM
Avidity Partners Management
Texas
-$41M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$26.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
VEA
176
Virtus ETF Advisers
New York
$156K -$9.27K -173 -5%
Ohio Public Employees Retirement System (OPERS)
177
Ohio Public Employees Retirement System (OPERS)
Ohio
$156K +$31.5K +588 +21%
SCM
178
Silvant Capital Management
Georgia
$129K – – –
ED
179
Exane Derivatives
France
$105K -$17.2K -321 -13%
MAM
180
Meeder Asset Management
Ohio
$95K +$34.8K +649 +47%
Osaic Holdings
181
Osaic Holdings
Arizona
$94K – – –
Macquarie Group
182
Macquarie Group
Australia
$84K – – –
Bessemer Group
183
Bessemer Group
New Jersey
$81K – – –
Lazard Asset Management
184
Lazard Asset Management
New York
$46K +$52.6K +982 New
Daiwa Securities Group
185
Daiwa Securities Group
Japan
$24K +$11.7K +218 +74%
PA
186
Parallel Advisors
California
$23K – – –
CAPTRUST Financial Advisors
187
CAPTRUST Financial Advisors
North Carolina
$21K +$14.4K +268 +150%
First Manhattan
188
First Manhattan
New York
$18K – – –
EW
189
Evoke Wealth
California
$15K – – –
LFG
190
Larson Financial Group
Missouri
$12K +$13.6K +253 New
MCM
191
Manchester Capital Management
Vermont
$12K +$13.6K +253 New
QCG
192
Quadrant Capital Group
Ohio
$10K +$268 +5 +2%
IUHSA
193
Itau Unibanco Holding S.A.
Brazil
$9K +$268 +5 +3%
TWA
194
TCI Wealth Advisors
Arizona
$7K – – –
BIA
195
Bell Investment Advisors
California
$6K +$6.86K +128 New
CTC
196
Central Trust Company
Missouri
$5K – – –
GRP
197
Global Retirement Partners
California
$5K – – –
SGAM
198
Smith Group Asset Management
Texas
$5K – – –
EWA
199
Evolution Wealth Advisors
Florida
$3K -$7.24K -135 -67%
US Bancorp
200
US Bancorp
Minnesota
$3K -$643 -12 -15%
6 7
8
9 10

BBIO Hedge Fund Activity: Q3 2021 in Review

210 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q3 2021, worth a combined $6.56B — down 22% from $8.46B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new BBIO positions and 18 closed out — a net gain of 12 holders — while 83 added to existing stakes and 61 trimmed.

The largest buyer was BlackRock, adding an estimated $34.4M. The largest seller was Vanguard Group, cutting an estimated $102M.

  • 210 institutional investors held BridgeBio Pharma (BBIO) as of Q3 2021, up from 200 in Q2 2021.
  • Funds reported $6.56B of BridgeBio Pharma stock for Q3 2021, down 22% quarter-over-quarter.
  • 30 funds opened new BridgeBio Pharma positions in Q3 2021 and 18 closed out, a net change of +12 holders.
  • The largest BridgeBio Pharma buyer in Q3 2021 was BlackRock, an estimated $34.4M added.
  • The largest BridgeBio Pharma seller in Q3 2021 was Vanguard Group, an estimated $102M sold.

Based on aggregated 13F filings for Q3 2021.